BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29382926)

  • 1. Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.
    Çelik H; Sciandra M; Flashner B; Gelmez E; Kayraklıoğlu N; Allegakoen DV; Petro JR; Conn EJ; Hour S; Han J; Oktay L; Tiwari PB; Hayran M; Harris BT; Manara MC; Toretsky JA; Scotlandi K; Üren A
    Oncogene; 2018 Apr; 37(16):2181-2196. PubMed ID: 29382926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clofarabine induces ERK/MSK/CREB activation through inhibiting CD99 on Ewing sarcoma cells.
    Sevim H; Çelik H; Düşünceli L; Ceyhan CS; Molotkova A; Nakazawa K; Graham GT; Petro JR; Toretsky JA; Üren A
    PLoS One; 2021; 16(6):e0253170. PubMed ID: 34133426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability.
    Balaraman K; Deniz E; Nelson E; Pilicer SL; Atasoy S; Molotkova A; Sevim H; Tiwari PB; Üren A; Wolf C
    Eur J Med Chem; 2023 May; 251():115244. PubMed ID: 36917882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.
    Manara MC; Terracciano M; Mancarella C; Sciandra M; Guerzoni C; Pasello M; Grilli A; Zini N; Picci P; Colombo MP; Morrione A; Scotlandi K
    Oncotarget; 2016 Nov; 7(48):79925-79942. PubMed ID: 27835596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth.
    Zhou F; Elzi DJ; Jayabal P; Ma X; Chiu YC; Chen Y; Blackman B; Weintraub ST; Houghton PJ; Shiio Y
    Cell Rep; 2020 Nov; 33(5):108332. PubMed ID: 33147457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation.
    De Feo A; Sciandra M; Ferracin M; Felicetti F; Astolfi A; Pignochino Y; Picci P; Carè A; Scotlandi K
    Cell Death Dis; 2019 Jun; 10(7):471. PubMed ID: 31209202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.
    O'Neill AF; Dearling JL; Wang Y; Tupper T; Sun Y; Aster JC; Calicchio ML; Perez-Atayde AR; Packard AB; Kung AL
    Clin Cancer Res; 2014 Feb; 20(3):678-87. PubMed ID: 24218512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation NKX2.2 IHC and
    Pasricha S; Pahwa S; Pruthi M; Jajodia A; Gupta G; Sharma A; Durga G; Kamboj M; Tiwari A; Panigrahi M; Mehta A
    Indian J Pathol Microbiol; 2023; 66(1):58-62. PubMed ID: 36656211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
    Satterfield L; Shuck R; Kurenbekova L; Allen-Rhoades W; Edwards D; Huang S; Rajapakshe K; Coarfa C; Donehower LA; Yustein JT
    Int J Cancer; 2017 Nov; 141(10):2062-2075. PubMed ID: 28748534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD99 Modulates the Proteomic Landscape of Ewing Sarcoma Cells and Related Extracellular Vesicles.
    De Feo A; Manfredi M; Mancarella C; Maqueda JJ; De Giorgis V; Pignochino Y; Sciandra M; Cristalli C; Donadelli M; Scotlandi K
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
    Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
    Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.
    Rocchi A; Manara MC; Sciandra M; Zambelli D; Nardi F; Nicoletti G; Garofalo C; Meschini S; Astolfi A; Colombo MP; Lessnick SL; Picci P; Scotlandi K
    J Clin Invest; 2010 Mar; 120(3):668-80. PubMed ID: 20197622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
    Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
    J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.
    Ikeda AK; Judelson DR; Federman N; Glaser KB; Landaw EM; Denny CT; Sakamoto KM
    Mol Cancer Ther; 2010 Mar; 9(3):653-60. PubMed ID: 20197394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor Regulation of Ewing Sarcoma Cell Function.
    Kersting N; Kunzler Souza B; Araujo Vieira I; Pereira Dos Santos R; Brufatto Olguins D; José Gregianin L; Tesainer Brunetto A; Lunardi Brunetto A; Roesler R; Brunetto de Farias C; Schwartsmann G
    Oncology; 2018; 94(6):383-393. PubMed ID: 29539615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
    Nanni P; Landuzzi L; Manara MC; Righi A; Nicoletti G; Cristalli C; Pasello M; Parra A; Carrabotta M; Ferracin M; Palladini A; Ianzano ML; Giusti V; Ruzzi F; Magnani M; Donati DM; Picci P; Lollini PL; Scotlandi K
    Sci Rep; 2019 Aug; 9(1):12174. PubMed ID: 31434953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.
    Vo KT; Edwards JV; Epling CL; Sinclair E; Hawkins DS; Grier HE; Janeway KA; Barnette P; McIlvaine E; Krailo MD; Barkauskas DA; Matthay KK; Womer RB; Gorlick RG; Lessnick SL; Mackall CL; DuBois SG
    Clin Cancer Res; 2016 Jul; 22(14):3643-50. PubMed ID: 26861456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary pancreatic Ewing sarcoma: a cytomorphologic and histopathologic study of 13 cases.
    Miller DL; Roy-Chowdhuri S; Illei P; James A; Hruban RH; Ali SZ
    J Am Soc Cytopathol; 2020; 9(6):502-512. PubMed ID: 32536453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.